CA2696776A1 — Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
Assigned to Ambit Bioscience Corp · Expires 2009-03-26 · 17y expired
What this patent protects
Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N'-[4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]ben-zothiazol-2-yl]phenyl}urea, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and…
USPTO Abstract
Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N'-[4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]ben-zothiazol-2-yl]phenyl}urea, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders are disclosed.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.